A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study
Abstract
:1. Introduction
2. Patients and Methods
2.1. Patients
2.2. Immunoassays
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Levi, M.; Thachil, J.; Iba, T.; Levy, J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020, 7, e438–e440. [Google Scholar] [CrossRef]
- Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb. Res. 2020, 191, 148–150. [Google Scholar] [CrossRef]
- Varga, Z.; Flammer, A.J.; Streiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020, 395, 1417–1418. [Google Scholar] [CrossRef]
- Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020, 383, 120–128. [Google Scholar] [CrossRef]
- Gelzo, M.; Cacciapuoti, S.; Pinchera, B.; De Rosa, A.; Cernera, G.; Scialò, F.; Mormile, M.; Fabbrocini, G.; Parrella, R.; Gentile, I.; et al. Prognostic role of neutrophil to lymphocyte ratio in COVID-19 patients: Still valid in patients that had started therapy? Front. Public Health 2021, 9, 664108. [Google Scholar] [CrossRef]
- Hirsch, S.J.; Ng, J.H.; Ross, D.W.; Sharma, P.; Shah, H.H.; Barnett, R.L.; Hazzan, A.D.; Fishbane, S.; Jhaveri, K.D.; Northwell COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020, 98, 209–218. [Google Scholar] [CrossRef]
- Duran, I.T.; Turkmen, E.; Dilek, M.; Sayarlioglu, H.; Arik, N. ANCA-associated vasculitis after COVID-19. Rheumatol. Int. 2021, 41, 1523–1529. [Google Scholar] [CrossRef] [PubMed]
- Csernok, E. The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis. Antibodies 2019, 8, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kallenberg, C.G.; Rarok, A.; Stegeman, C.A.; Limburg, P.C. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun. Rev. 2002, 1, 61–66. [Google Scholar] [CrossRef]
- Giles, I.; Salama, A.D. The autoimmune rheumatic diseases—An introduction. Medicine 2018, 46, 77. [Google Scholar] [CrossRef]
- Sy, A.; Khalidi, N.; Dehghan, N.; Barra, L.; Carette, S.; Cuthbertson, D.; Hoffman, G.S.; Koening, C.L.; Langford, C.A.; McAlear, C.; et al. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin. Arthritis Rheum. 2016, 45, 475–482. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghosh, K.; Pradhan, V.; Ghosh, K. Background noise of infection for using ANCA as a diagnostic tool for vasculitis in tropical and developing countries. Parasitol. Res. 2008, 102, 1093–1095. [Google Scholar] [CrossRef]
- Flores-Suárez, L.F.; Cabiedes, J.; Villa, A.R.; van der Woude, F.J.; Alcocer-Varela, J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology 2003, 42, 223–229. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Sawalha, A.H.; Lu, Q. COVID-19 and autoimmune diseases. Curr. Opin. Rheumatol 2021, 33, 155–162. [Google Scholar] [CrossRef]
- Zollo, M.; Ferrucci, V.; Izzo, B.; Quarantelli, F.; Di Domenico, C.; Comegna, M.; Paolillo, C.; Amato, F.; Siciliano, R.; Castaldo, G.; et al. SARS-CoV_Subgenomic N (sgN) transcripts in oro-nasopharingeal swabs correlate with the highest viral load, as evaluated by five different methods. Diagnostics 2021, 11, 288. [Google Scholar] [CrossRef]
- Von Cube, M.; Grodd, M.; Wolkewitz, M.; Hazard, D.; Wengenmayer, T.; Canet, E.; Lambert, J. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information. Crit. Care Med. 2021, 49, e11–e19. [Google Scholar] [CrossRef] [PubMed]
- WHO Working Group on the Clinical Characterization and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis 2020, 20, e192–e197. [Google Scholar] [CrossRef]
- Cacciapuoti, S.; De Rosa, A.; Gelzo, M.; Megna, M.; Raia, M.; Pinchera, B.; Pontarelli, A.; Scotto, R.; Scala, E.; Scarano, F.; et al. Immunocytometric analysis of COVID patients: A contribution to personalized therapy? Life Sci. 2020, 261, 118355. [Google Scholar] [CrossRef]
- Nakada, Y.; Tsuboi, N.; Takahashi, Y.; Yoshida, H.; Hara, Y.; Okonogi, H.; Kawamura, T.; Arimura, Y.; Yokoo, T. A Case of Concurrent MPO-/PR3-Negative ANCA-Associated Glomerulonephritis and Membranous Glomerulopathy. Case Rep. Nephrol. 2015, 2015, 316863. [Google Scholar] [CrossRef] [Green Version]
- Kaplan, M.J.; Radic, M. Neutrophil extracellular traps (NETs): Double-edged swords of innate immunity. J. Immunol. 2012, 189, 2689–2695. [Google Scholar] [CrossRef] [Green Version]
- Land, J.; Rutgers, A.; Kallenberg, C.G.M. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: Pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol. Dial. Transplant. 2014, 29, 739–745. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ramponi, G.; Folci, M.; De Santis, M.; Damoiseaux, J.G.M.C.; Selmi, C.; Brunetta, E. The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. Autoimmun. Rev. 2021, 20, 102759. [Google Scholar] [CrossRef] [PubMed]
- Xu, P.; Cui, Z.; Chen, M.; Hellmark, T.; Zhao, M.H. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology 2011, 50, 1236–1243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Controls | Asymptomatic | Hospitalized | Kruskal–Wallis | |
---|---|---|---|---|
N | 48 | 16 | 108 | - |
Age (years) | 43 (33–61) | 49 (42–61) | 41 (32–61) | n.s. |
ANCAs (ng/mL) | 5.1 (4.7–6.1) | 4.3 (2.8–4.7) a | 6.5 (5.0–8.1) a,b | <0.0001 |
MPO (ng/mL) | 413 (249–548) | 533 (389–667) a | 396 (312–669) | n.s. |
PR3 (ng/mL) | 1.3 (1.1–1.7) | 1.0 (0.5–1.8) | 1.4 (0.9–2.6) | n.s. |
Wave | WHO 3 | WHO 4 | WHO 5–7 | Kruskal–Wallis | |
---|---|---|---|---|---|
N | 1st | 7 | 20 | 8 | - |
2nd | 45 | 16 | 12 | - | |
Age | 1st | 60 (39–62) | 64 (51–73) | 75 (57–79) | n.s. |
(years) | 2nd | 32 (28–39) | 34 (30–49) | 51 (44–56) a,b | <0.0001 |
1st versus 2nd | 0.016 | 0.001 | 0.016 | ||
ANCA | 1st | 5.4 (3.3–9.6) | 5.5 (3.9–7.7) | 12.5 (3.8–14.4) | n.s. |
(ng/mL) | 2nd | 5.8 (5.0–7.4) | 7.3 (5.4–9.3) a | 8.7 (7.3–9.1) a | <0.0001 |
1st versus 2nd | n.s. | n.s. | n.s. | ||
MPO | 1st | 658 (477–775) | 878 (598–999) | 994 (785–1046) | n.s. |
(ng/mL) | 2nd | 365 (308–459) | 327 (255–404) | 341 (317–355) | n.s. |
1st versus 2nd | 0.008 | <0.0001 | 0.004 | ||
PR3 | 1st | 1.2 (0.8–2.3) | 3.0 (1.9–3.9) a | 4.0 (2.8–9.1) a | 0.041 |
(ng/mL) | 2nd | 1.1 (0.8–1.7) | 1.1 (0.9–1.6) | 1.2 (0.8–1.6) | n.s. |
1st versus 2nd | n.s. | <0.0001 | <0.0001 |
WHO 3 (n = 18) | WHO 4 (n = 24) | WHO 5–7 (n = 10) | ||
---|---|---|---|---|
ANCA | Basal | 6.3 (4.7–7.7) | 7.5 (4.9–9.0) | 8.1 (7.1–12.6) |
(ng/mL) | After 1 week | 6.8 (4.8–8.0) | 5.7 (4.4–8.9) | 6.2 (6.0–6.8) |
p-value a | n.s. | n.s. | 0.043 | |
MPO | Basal | 466 (353–667) | 570 (334–898) | 794 (323–1034) |
(ng/mL) | After 1 week | 474 (367–731) | 612 (341–958) | 551 (362–1161) |
p-value a | n.s. | n.s. | n.s. | |
PR3 | Basal | 1.3 (0.8–2.3) | 2.3 (1.6–3.7) | 2.9 (1.4–6.6) |
(ng/mL) | After 1 week | 1.8 (1.0–2.5) | 1.9 (1.2–2.7) | 1.7 (1.5–2.2) |
p-value a | 0.022 | n.s. | n.s. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gelzo, M.; Cacciapuoti, S.; Pinchera, B.; De Rosa, A.; Cernera, G.; Scialò, F.; Comegna, M.; Mormile, M.; Gallicchio, A.; Fabbrocini, G.; et al. A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study. Viruses 2021, 13, 1718. https://doi.org/10.3390/v13091718
Gelzo M, Cacciapuoti S, Pinchera B, De Rosa A, Cernera G, Scialò F, Comegna M, Mormile M, Gallicchio A, Fabbrocini G, et al. A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study. Viruses. 2021; 13(9):1718. https://doi.org/10.3390/v13091718
Chicago/Turabian StyleGelzo, Monica, Sara Cacciapuoti, Biagio Pinchera, Annunziata De Rosa, Gustavo Cernera, Filippo Scialò, Marika Comegna, Mauro Mormile, Antonella Gallicchio, Gabriella Fabbrocini, and et al. 2021. "A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study" Viruses 13, no. 9: 1718. https://doi.org/10.3390/v13091718
APA StyleGelzo, M., Cacciapuoti, S., Pinchera, B., De Rosa, A., Cernera, G., Scialò, F., Comegna, M., Mormile, M., Gallicchio, A., Fabbrocini, G., Parrella, R., Corso, G., Gentile, I., & Castaldo, G. (2021). A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study. Viruses, 13(9), 1718. https://doi.org/10.3390/v13091718